Loading…
Loading…
VOR does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for VOR and 80,000+ other tickers.
See exactly how VOR's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for VOR and 80,000+ other tickers.
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer…
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 59,250 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,550 shares of Vor Bio's common stock to 9 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report)'s stock price was up 5.3% on Wednesday. The stock traded as high as $19.30 and last traded at $19.3050. Approximately 100,789 shares changed hands during trading, a decline of 91% from the average session volume of 1,068,548 shares. The stock had previously closed at $18.33. Wall Street
More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over the first 24 weeks After achieving MSE, 86.7% of MSE events were sustained at the next monthly assessment and participants spent 83-85% of remaining study follow-up in MSE Approximately 51% of participants with baseline MG-ADL scores of 6-10 and 21% of participants with baseline MG-ADL scores ≥11 achieved MSE BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced a new post hoc analysis from the Phase 3 trial conducted in China by its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), evaluating telitacicept in adults with generalized myasthenia gravis (gMG).